Comparison of immunogenicity for Sinovac-CoronaVac vaccine vs. natural infection during cancer treatment

Simple item page
dc.contributor.authorÇakir, E
dc.contributor.authorSaydan, D
dc.contributor.authorGülbagci, B
dc.contributor.authorÖzen, M
dc.contributor.authorUgurlu, I
dc.contributor.authorDemirci, A
dc.contributor.authorBilir, F
dc.contributor.authorHacibekiroglu, I
dc.contributor.authorYildiz, N
dc.contributor.authorAkcali, S
dc.contributor.authorAltindis, M
dc.contributor.authorVarim, C
dc.contributor.authorYaylaci, S
dc.contributor.authorBilir, C
dc.date.accessioned2025-04-10T10:34:53Z
dc.date.available2025-04-10T10:34:53Z
dc.description.abstract- OBJECTIVE: Efficacy of the COVID-19 vaccines in cancer patients, especially during their active treatment, are lacking. Most of the studies in the literature compared the immuni-ty in cancer patients with a cross-sectional cohort or retrospectively. Our study investigated Sino-vac-CoronaVac COVID-19 vaccine immunogenici-ty and compared it with natural COVID-19 disease in cancer patients during their cancer therapy.PATIENTS AND METHODS: A total of 111 pa-tients with cancer and who are on active treat-ment were included in the study. This is a sin-gle-center study and was designed prospec-tively. Two group of patients were included in the study, natural disease and vaccinated group.RESULTS: A total of 111 patients were in-cluded in the study, 34 of whom had natural COVID-19 disease. Antibody levels following the first dose vaccine were 0.4 (0-1.9) U/ml while af-ter the second dose of vaccine were 2.6 (1.0-7.25) U/ml. Immunogenicity levels were 82.4% in the natural disease group and 75.8% in the vaccinated group after the second shot of the vaccine. Immunogenicity rate was significantly higher in non-chemotherapy (receiving immu-notehrapy/targeted therapy or biologic agent) group compared to chemotherapy drug (92.9% vs. 63.3%, p=0.004). There was a difference be-tween the antibody levels following the first and second vaccination [median (IQR): 0.3 (0-1.0) and 3.3 (2.0-6.7), p=0.001, respectively].CONCLUSIONS: The present study revealed that the Sinovac-CoronaVac vaccine showed an acceptable immunogenicity following two shots in cancer patients who were receiving ac-tive systemic therapy. On the other hand, nat-ural disease immunogenicity was higher than vaccinated group.
dc.identifier.issn1128-3602
dc.identifier.urihttp://hdl.handle.net/20.500.14701/40988
dc.language.isoEnglish
dc.titleComparison of immunogenicity for Sinovac-CoronaVac vaccine vs. natural infection during cancer treatment
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu